Patient Satisfaction with Psoriasis Therapies: An Update and Introduction to Biologic Therapy

Finlay, A.Y.; Ortonne, Jean‐Paul

doi:10.1007/s10227-005-0030-6

Cited by 34 publications

(9 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, the majority of respondents were very satisfied with biologics. This is consistent with previous studies that had reported high satisfaction rates amongst patients using biologic therapies(10, 11). Thus, physicians should not hesitate to tell patients who are considering starting biologics that despite the risks of adverse effects or not responding to these medications, the great majority of patients on biologics are satisfied with their treatment.…”

Section: Discussionsupporting

confidence: 93%

How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center

Kamangar

Isip

Bhutani

et al. 2011

Journal of Dermatological Treatment

View full text Add to dashboard Cite

The availability of new biologic agents for the treatment of psoriasis provides hope for improved quality of life outcomes. However, the way patients come to use biologics, potential barriers they encounter, and their attitudes towards using these medications are still not well studied. Here, we conducted a survey of 106 psoriasis patients at an academic medical center to discern patient attitudes towards biologics. We found that most patients learn of biologics through their physician and perform follow-up research using the Internet. Most patients did not find it difficult to make the decision to start a biologic. Difficulty in obtaining biologics was associated with age less than 55 (p=0.01), lower income level (p=0.007), and lack of insurance (p=0.04). Patients were found to have high satisfaction and compliance rates on biologics. Of patients who missed a dose of their biologic, this was mainly due to logistical reasons such as not having the medication or forgetting to take it, rather than being depressed or overwhelmed. Patients with lower income levels had increased cutbacks in personal expenses due to co-payments (p=0.001). Among respondents, the mean annual out of pocket expense for a biologic was $557.12 per year, with a range of $0 to $7,000.

show abstract

Section: Discussionsupporting

confidence: 93%

How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center

Kamangar

Isip

Bhutani

et al. 2011

Journal of Dermatological Treatment

View full text Add to dashboard Cite

show abstract

“…Inadequate responses reported by patients as no change or even worsening of disease with treatment from 10% to 50%. Usually, nonbiologic therapies have a very high degree of dissatisfaction from the patients (Nijsten et al 2005;Finlay and Ortonne 2004) and the inconvenience and safety of traditional therapies become an issue for the patients. On the other hand, cyclosporine, methotrexate, and acitretin were qualified as highly effective in another survey (Strober et al 2006).…”

Section: Discussionmentioning

confidence: 99%

XP-828L (Dermylex), a new whey protein extract with potential benefit for mild to moderate psoriasisThis article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products.

Drouin

Lamiot

Cantin

et al. 2007

Can. J. Physiol. Pharmacol.

View full text Add to dashboard Cite

Natural health products (NHPs) or complementary and alternative medicine (CAM) are commonly used to prevent disorders or support the usual treatments of many diseases. XP-828L, a whey protein extract, has demonstrated potential benefits for the treatment of mild to moderate psoriasis. The aim of this study was to analyze further clinical data that demonstrated the clinical benefits and safety of the XP-828L in patients with psoriasis and the potential mechanism of action of this product in vitro. Oral administration (2.5 g, twice a day, over 112 days) of XP-828L in 42 human subjects with mild to moderate psoriasis improved their PGA scores (physician's global assessment). Moreover, no significant changes in haematology or hepatic and renal parameters were observed throughout the study period, indicating the safety of the product. In vitro experiments showed that XP-828L decreased the proliferation of concanavalin A (ConA)-stimulated murine splenocytes and their production of interleukin (IL)-2 and interferon (IFN)-gamma. Although the in vivo mechanism of action of XP-828L remains unknown, XP-828L represents an NHP to be used as an alternative or concomitant treatment for mild to moderate psoriasis and potentially for other immune-mediated diseases.

show abstract

“…Development of new biologics is favored because traditional topical therapies, phototherapy, and systemic medications have been associated with patient frustration10 and low compliance 11,12. Furthermore, topical treatments and phototherapy do not improve joint damage that is ongoing in psoriatic arthritis, and traditional systemic agents can cause long-term organ damage, such as pulmonary fibrosis and cirrhosis in patients on methotrexate.…”

Section: Introductionmentioning

confidence: 99%

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis

Ren¹,

Dao²

2013

CCID

View full text Add to dashboard Cite

BackgroundPsoriasis is a debilitating autoimmune skin disease that affects 2%–3% of the world’s population. Patients with moderate-to-severe plaque psoriasis suffer from a decreased quality of life as well as comorbidities. Newer biological agents have been shown to be more effective than traditional therapies. In this article, we assess the potential role of ixekizumab, an anti-interleukin (IL)-17 antibody, in treating moderate-to-severe plaque psoriasis.MethodWe reviewed PubMed for articles regarding ixekizumab and the epidemiology and management of plaque psoriasis.ResultsIn a Phase I clinical trial, treatment with ixekizumab resulted in both clinical and histopathologic improvement of psoriasis, which suggests that IL-17 may be a key driver in the pathogenesis of psoriasis. In a Phase II clinical trial, treatment with ixekizumab resulted in rapid clinical improvement of psoriasis, which lends further support to its role as an effective treatment for patients with chronic moderate-to-severe plaque psoriasis. Reductions in Psoriasis Area and Severity Index (PASI) score are comparable to those associated with currently marketed biologics.ConclusionLiterature concerning the effects of ixekizumab on chronic moderate-to-severe plaque psoriasis is currently limited to two clinical trials. Results suggest that ixekizumab shows great therapeutic promise. However, more large-scale and long-term trials are needed to establish safety and efficacy.

show abstract

Patient Satisfaction with Psoriasis Therapies: An Update and Introduction to Biologic Therapy

Abstract: Biologic agents offer new hope for patients with psoriasis that their chronic condition can be controlled in a manner that improves their quality of life and may lead to high levels of satisfaction with their treatment.

Cited by 34 publications

References 72 publications

How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center

How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center

XP-828L (Dermylex), a new whey protein extract with potential benefit for mild to moderate psoriasisThis article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products.

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis

Contact Info

Product

Resources

About